Natera: A Growing Biotech, After Recent FDA Approval And Q1 Revenue Results
Natera, Inc. has received a reaffirmed buy rating following recent FDA approval and strong Q1 revenue results. The company's revenue grew by 38% year-over-year, indicating robust operational momentum. Analysts expect Natera to achieve profitability by FY28 despite current unprofitability.
- ▪Natera's Q1 revenue increased by 38% year-over-year.
- ▪Test volumes rose by 18.5%, showcasing strong market demand.
- ▪Analysts predict Natera will reach profitability by FY28.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4909107-natera-stock-growing-biotech-after-recent-fda-approval-and-q1-revenue-results"},"author":{"@type":"Person","name":"Albert…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
